Braun Stacey Associates Inc. boosted its holding in Encompass Health Corporation by 9.3% during the third quarter, acquiring an additional 18,967 shares to reach a total of 223,673 shares. At the end of the period, the firm’s position represented 0.22% of the company’s outstanding shares and carried a book value of approximately $28.4 million, according to the latest SEC filing.

Recent filings show that Norges Bank established a new position valued at roughly $139.5 million in the second quarter, while Congress Asset Management added about $92.7 million and 8 Knots Management invested nearly $78.6 million during the same period. Other notable entrants include Strs Ohio with a $34.4 million commitment and Marshall Wace LLP with $34.7 million. Collectively, hedge funds and institutional investors now hold 97.25% of Encompass Health’s shares.

Five research firms have updated their outlooks for Encompass Health over the past two months. Wall Street Zen upgraded the rating to buy, Raymond James Financial raised it to strong-buy, and UBS Group increased its price target by 7.1%. While Zacks Research lowered its recommendation from strong-buy to hold, Weiss Ratings reaffirmed a buy (b+) stance. Of the eleven analysts covering the stock, two assign a strong-buy, eight a buy and one a hold, yielding an average target above consensus levels.

In its latest quarterly report, Encompass Health delivered earnings per share of $0.93 on revenue of $136.3 million, generating a net margin of 9.33% and a return on equity of 17.84%. The company set full-year guidance in the range of $3.83 to $4.19 EPS, while analysts project $4.80 for the current fiscal year. Meanwhile, management declared a quarterly dividend of $0.19 per share, payable January 15 to holders of record January 2, implying an annualized payout ratio of 14.37%.